Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | PHGDH | O43175 | 10/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16595666 | 0.86 | LMNA (0.47) | RXFP1PHGDHMEN1KMT2AL3MBTL1 | |
| SCHEMBL16595667 | 0.85 | RXFP1 (0.47) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL8899522 | 0.78 | RXFP1 (0.43) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL20799418 | 0.76 | AGPAT2 (0.47) | RXFP1PHGDHKMT2A | |
| SCHEMBL4919697 | 0.73 | L3MBTL1 (0.70) | RXFP1PHGDHMEN1KMT2AL3MBTL1 | |
| SCHEMBL20799416 | 0.69 | MAOB (0.46) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL23457134 | 0.68 | MEN1 (0.46) | MEN1KMT2A | |
| SCHEMBL43328 | 0.67 | KDM4E (0.66) | RXFP1PHGDHMEN1KMT2AAHR | |
| SCHEMBL17324809 | 0.67 | RXFP1 (0.64) | RXFP1PHGDHMEN1KMT2AL3MBTL1 | |
| SCHEMBL1253301 | 0.67 | RXFP1 (0.72) | RXFP1PHGDHMEN1KMT2AAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | RXFP1 4460/4885PHGDH 610/4885MEN1 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.